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Background: Disclosure of individual results to participants in genomic research is a complex and contentious
issue. There are many existing commentaries and opinion pieces on the topic, but little empirical data concerning
actual cases describing how individual results have been returned. Thus, the real life risks and benefits of disclosing
individual research results to participants are rarely if ever presented as part of this debate.
Methods: The Australian Pancreatic Cancer Genome Initiative (APGI) is an Australian contribution to the
International Cancer Genome Consortium (ICGC), that involves prospective sequencing of tumor and normal
genomes of study participants with pancreatic cancer in Australia. We present three examples that illustrate
different facets of how research results may arise, and how they may be returned to individuals within an ethically
defensible and clinically practical framework. This framework includes the necessary elements identified by others
including consent, determination of the significance of results and which to return, delineation of the responsibility
for communication and the clinical pathway for managing the consequences of returning results.
Results: Of 285 recruited patients, we returned results to a total of 25 with no adverse events to date. These
included four that were classified as medically actionable, nine as clinically significant and eight that were returned
at the request of the treating clinician. Case studies presented depict instances where research results impacted on
cancer susceptibility, current treatment and diagnosis, and illustrate key practical challenges of developing an
effective framework.
Conclusions: We suggest that return of individual results is both feasible and ethically defensible but only within
the context of a robust framework that involves a close relationship between researchers and clinicians.Background
It is generally agreed in national and international ethical
guidelines that, broadly, the results of research should be
made available to participants [1,2] and this is echoed in
the literature on this topic [3,4]. This has generally been re-
stricted to aggregate data that are made available through
written publications such as journal articles or through re-
search websites. Individuals are not identifiable in such ag-
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unless otherwise stated.usually reported back to participants, although arguments
have been made that individual results should be made
available in some circumstances [5-7].
Since the first draft of the sequence of the human gen-
ome [8,9] there has been a literal revolution in the way in
which genomic sequencing is performed. Over the past
decade, next-generation sequencing (NGS) has developed
to the point that rapid and relatively affordable sequencing
of individual genomes is a reality [10]. NGS offers the
promise of tremendous public benefit as it underpins both
improvements in our understanding of disease as well as
substantially changing our practical ability to translate this
knowledge through improved diagnostics and therapeu-
tics. The advent of NGS has also seen an increase in thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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genomic data to research participants.
Knoppers et al. [11] previously commented that return-
ing individual results appears to be contrary to the funda-
mental purpose of research, but noted that if this was to
occur, it should be addressed in consent documentation
prior to participation. Similarly, Forsberg et al. [12] argued
against the return of results from research on the basis
that it is a collective effort to improve public health and
that this could be seen as a shift from autonomy and indi-
vidual rights to collective responsibility and solidarity.
Nevertheless some have argued that there may be an obli-
gation to return individual results, and Beskow and Burke
[13] proposed a model based on an ancillary care frame-
work as the basis for evaluating when such obligations
may arise. Similarly, Ravitsky and Wilfond [14] suggest
that different results may require different decisions even
within the same study, and Renegar et al. [15] describe a
benefit-to-risk assessment to balance the potential positive
versus negative consequences to participants. Fabsitz et al.
[16] outlined five principles for determining if research
results should be returned to individuals and these are
echoed by Amy McGuire and colleagues’ [17] recom-
mendations. In brief, these identify a need to obtain ap-
propriately informed consent, to ensure that any results
are analytically valid, that there is potential for inter-
vention based on the results, that there are mechanisms
in place to return results, and that adequate resources
exist to do so.
These commentaries have permitted researchers to de-
cide primarily not to return results for practical reasons;
however, Wolf et al. [6] recently argued that there is a
responsibility to establish frameworks for return of indi-
vidual results as a core component of any research. In
contrast, Bledsoe et al. [18] have proposed that context
is important, and rather than a generalized obligation,
careful evaluation based upon the type of research and
likely clinical utility be considered. The American Col-
lege of Medical Genetics has recently suggested that the
use of NGS in clinical practice may give rise to an obli-
gation to actively search for 57 (revised to 56) genes
linked to 24 genetic conditions [19]. Whilst this is only a
recommendation for clinical practice (with a disclaimer),
policy makers are noting these documents and there is
the potential for this to become a more general obliga-
tion for both clinical practice and research. The Presi-
dential Commission for the Study of Bioethical Issues,
with the Office of the Secretary, Department of Health
and Human Services in the United States of America are
currently reviewing this approach.
This has become an issue of global importance because
projects like the International Cancer Genome Consortium
(ICGC) and the international Rare Diseases Consortium
(IRDiRC) involve the exchange of genetic data across manyborders [20]. Indeed, the creation of large-scale genomic
data repositories available to external researchers implies
that there are no borders when it comes to these data, and
therefore international harmonization of guidelines will
prove to be vital. Statements by the 1991 Council for Inter-
national Organizations of Medical Sciences (CIOMS) [21]
and the Council of Europe [22] already suggest that it may
be reasonable to return individual information arising from
genomic studies in specific contexts.
An ethical obligation to establish a plan for returning
potentially relevant findings exists within the Australian
National Statement on Ethical Conduct in Human Research
[2]. Researchers are required to consider the likelihood of
making any such findings and to have an ‘ethically defens-
ible plan’ to withhold or disclose these. Whatever the plan,
there is an obligation to notify potential research partici-
pants about the risks involved during the consent process
and to have appropriate mechanisms that will handle re-
turn of any individual results as they arise.
Whilst the published reports and opinions are helpful,
to the best of our knowledge there appears to be few em-
pirical data on or evaluations of actual situations involving
return of research results. In this article we present data
from The Australian Pancreatic Cancer Genome Initiative
(APGI), an Australian contribution to the ICGC, where
individual research results were returned to participants
and the impact and challenges of this process explored.
We present the framework for which return of results has
been constituted and provide an overview of case studies
where research data were returned. We use these exam-
ples to illustrate how our framework worked in practice,
discuss the ethical and practical challenges encountered,
and make recommendations based on our experiences.
Methods
Study population
The APGI [23] is a multi-disciplinary research network in
Australia, with over 100 active contributors. The goal of
the APGI is to comprehensively catalogue the genomic ab-
normalities in 375 prospectively recruited pancreatic can-
cer patients by high-throughput NGS [24]. The study
includes recruitment of participants undergoing surgical
treatment for pancreatic cancer, collection of tissue and
blood specimens and subsequent sequencing of the entire
genomes of tumor and matched normal DNA, and profil-
ing of gene expression and methylation states [25,26]. Eth-
ical approval was obtained from the human research ethics
committee at each participating institution, conducted in
accordance with the National Statement on Ethical Con-
duct in Human Research (2007) and the Declaration of
Helsinki (Additional file 1). All participants provided writ-
ten informed consent upon entry to the study, which in-
cluded their preference with respect to return of results.
Additionally, written informed consent was obtained from
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of the consent form is available to the Editor on request.
Establishing an ethically defensible and clinically practical
framework - the ethically defensible plan
The Australian National Statement on ethical conduct in
Human Research (2007) section 3.5.1 states 'Where re-
search may discover or generate information of potential
importance to the future health of participants, or their
blood relatives, researchers must prepare and follow an
ethically defensible plan to disclose or withhold that in-
formation'. What is key about this guideline is that it
does not assume an obligation to return results but in
essence enacts Beskow and Burke’s [13] proposal to es-
tablish context-dependent mechanisms for when and
how research results should be returned.
Given the obligation in Australia to consider this guide-
line, the framework set out by the APGI for returning re-
sults employs a context-dependent approach, and enacts a
category-based system for the characterization of research
findings as previously proposed [27]. The framework was
developed as an iterative, evidence-based and consensus
driven process, with engagement of key stakeholders
within the APGI, including surgeons, oncologists, scien-
tists, ethicists and clinical geneticists. Importantly, the
plan is reviewed annually, to keep pace with advances in
technology and emerging reference data. The central com-
ponents of the framework are informed consent, analytical
validity, clinical relevance or significance of the finding,
communicability and delivery of results (Additional file 2).
Consent
Through the consent process, participants are provided
with information in relation to the fact that relevant find-
ings may be discovered in the course of the study, and that
these may not be limited to pancreatic cancer. The consent
process allows participants the choice to 'opt in' to have in-
dividual results communicated, and given the short survival
of many individuals with pancreatic cancer, the choice of to
whom else they may be communicated. It is usual practice
during the consent process to obtain contact details of a
family member or significant other who is identified to re-
ceive information (Additional file 3). Whilst participation of
family members in the consent process is typical and was
encouraged for the above reasons, relatives are not consid-
ered formal participants of the study and explicit consent
was not required under this protocol. Participants are in-
formed that any information would initially be discussed
with their treating doctor, and their preference for returning
results is logged and tracked through a research database.
Significance of findings
We focused on cancer-related incidental findings and
segregated our data into three categories of significancebased on available evidence [27,28] and clinical consen-
sus amongst APGI clinical specialists (Table 1). Whilst
there is a great deal of debate about where one may
draw the line between categories and which genes may
fall into each [19], we made a practical, project-directed
decision, where findings were related to the research
indication.
Communication strategy
Communicability considers the practicality of communi-
cating results, the circumstances of the participant and
treating clinician, while delivery of results considers how
best the results could be communicated. In the APGI
study, participants are initially contacted in writing, and
invited to contact the research team via telephone. They
are given the option of receiving the information face-
to-face, which, in our opinion, is the best method of de-
livery in sensitive situations. Wherever allowable, results
are to be communicated to the clinical care provider or
treating medical team for their consideration. At times
the delivery will take place face-to-face in a multidiscip-
linary setting, with the participant, family, clinicians and
researchers present. Contact information of participants
is collected via an interview performed at the time in-
formed consent is obtained.
Results
Since June 2009, 556 participants have been enrolled as
part of the APGI. As with previous studies [32,33], our
population was very willing to be contacted, with 95%
(n = 530) indicating through the consent process that they
would like to be contacted and notified about important
research information. Furthermore, 100% of those that
agreed to be contacted (n = 530) also agreed to provide
contacts for a family member or significant other should
they not be available to receive the information.
Variant calling
SNPs were identified with a dual-calling strategy using
qSNP [34] and GATK [35], while small insertions and
deletions (indels) were called with Pindel [36]. Variants
that were specific to the tumor sample with no evidence
in the matched germline sample were considered som-
atic, while those present in the germline sample and the
tumor sample or specific to the germline sample were
classified as germline. Germline SNPs identified by
GATK and/or qSNP were marked as 'PASS' if they con-
tained at least five sequence reads containing the variant
with a minimum of four novel starts. If a germline SNP
was detected by both GATK and qSNP, it was consid-
ered high-confidence. Germline indels were filtered to
include those with a minimum of three novel starts. All
germline variants were annotated using ENSEMBL v70
and dbSNP130 and those in genes of interest underwent
Table 1 Categories of significance and evidence and examples of genes and pathways included in the various
categories felt to be specific to this protocol
Category Key criteria Examples of genes or pathways Justification and evidence
Medically actionable Analytically validated assay Highly penetrant variants in cancer-related
genes associated with disorders
Certified and established clinical or
practice guidelines
Clinical validity ATM Direct clinical utility of a diagnostic
or therapeutic nature that is part of
accepted clinical practice
Direct clinical utility (established
guidelines with regard to prevention,
diagnosis, prognostication and/or
therapy)
MLH1, MSH6, MSH2 PMS2 Preventable disease due to
established treatment approaches
APC Diagnostic grade assay available in
standard clinical practice
BRCA1 or BRCA2
PALB2
MUTYH
VHL
MEN1, RET
NF2
STK11
TP53
Potential clinical utility Clinical validity ERBB2 (HER 2/neu) amplification [29] Scientific literature (high level of evidence)
Clinical utility not proven in current
treatment setting
Defects in genes involved in homologous
recombination [30]
Pre-clinical evidence
Availability of clinical trials specific to
the finding
Mutations of EGFR, KIT, BRAF, BRCA1/2,
PALB2, where therapeutics are potentially
accessible and clinically appropriate
Clinical trial signals
Wild-type KRAS [31] Therapeutic opportunity:
Drug repurposing
Rescuing therapeutics
Clinical trial availability
Diagnostic grade assay available
Potentially highly replicable robust
single laboratory research assay
Undetermined significance Variants that have not as yet been
definitively linked to a phenotype,
clinical outcome or intervention
Not applicable These variants form the basis of
future research
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ically focused on due to practical actionability are outlined
in Table 1. In addition, unusual or outlier mutational sig-
natures were also examined.
High-confidence germline calls in candidate genes were
further annotated with standard tools [38] assessing the
amino acid sequence change, minor allele frequency and
predicted impact on protein function. All frameshift
indels, truncating single-nucleotide variants and missense
single-nucleotide variants that were deemed possibly dam-
aging, or with qualitative scores indicating the finding was
deleterious, were further investigated using inherited dis-
ease mutation databases [39] and literature review. Those
previously reported as pathogenic with functional evi-
dence were then sent for confirmatory testing using a
diagnostic grade assay. Other variants were not consideredsufficiently validated or lacked supporting evidence to re-
turn as individual results.
Of the 556 participants, 285 underwent genomic se-
quencing and 17 medically actionable or clinically useful
findings were validated and returned (Additional file 4).
In addition, clinicians participating in the study directly
requested results on an additional eight participants that
did not have results that were medically actionable or of
potential clinical utility. Out of the 17 results that were
returned, 4 represented germline susceptibility muta-
tions, 3 had genomic changes that altered diagnosis, and
10 had potential therapeutic relevance. With the excep-
tion of one case where the diagnosis was in question, all
results were confirmed in independent, diagnostic grade
assays. Most results (15; 88%) were communicated to
treating clinical teams or primary care providers, and 2
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of kin. Twelve (70%) were actioned and resulted in an
intervention, either influencing a clinical decision or
prompting involvement in a screening program. No ad-
verse events were reported with the return of results
process. Our three cases were selected as representative
of the types of cases we encountered, and are illustrative
of the specific categories we define in this framework.
Case studies
Case study 1: category 1 (medically actionable finding) -
inherited predisposition to cancer with relevance to
other family members
Scenario A 78 year old Female underwent surgery for
pancreatic cancer and provided standard APGI consent.
Significance of finding Germline analysis revealed the
presence of a deleterious mutation in exon 11 of the
BRCA2 gene (c.5239insT). This mutation is expected to
produce the BRCA2 inherited breast cancer phenotype.
This mutation confers a 49% lifetime risk of breast can-
cer and 18% lifetime risk for ovarian cancer [40]. To ob-
tain independent confirmation, this result was verified in
a diagnostic laboratory with an accredited assay [41].
Description of ethical and practical issues The partici-
pant was deceased at the time the results became avail-
able. Following the ethically defensible plan, after
discussion with a cancer geneticist, the listed next of kin,
the participant’s son, was sent a letter with an invitation
to contact the research team to discuss results. After re-
ceiving the letter, contact was made within one week
where findings were discussed in general terms, and a
referral was given to a familial cancer clinic for counsel-
ing and further testing. In the meantime, the research
team communicated the specific findings to the local fa-
milial cancer clinic. This was an important part of the
process and it enabled the genetic counselors to consider
the specific sensitivities related to this case, and plan ap-
propriate intake procedures. At subsequent appoint-
ments with the familial cancer clinic, the son and two
daughters were identified to have inherited the BRCA2
mutation. The participant’s son has joined a pancreatic
and prostate cancer screening program at his local hos-
pital, and his sisters have undergone risk reduction sur-
gery. Several months later, the research team followed up
with the participant directly and he expressed sincere
gratitude for receiving the information. He said 'For me,
knowledge is power. I am now more informed about my
future health'.
Conclusions and recommendations The major consid-
eration here was the communication strategy with thenext of kin given the fact that the participant was de-
ceased and the next of kin had no overlapping or on-
going relationship with any clinical care provider.
Australian privacy law [42] does not address the use of
information from deceased persons. However, an im-
portant amendment to the privacy act [43] allows for
communication with family members without consent of
a person under their care if a medical practitioner feels
there is a risk of harm to them arising from knowledge
about that person. In our case, participants were given
the option of identifying a contact person in the event of
their death, but not all family members may have been
aware of the possibility that research was being done
that could generate information that could have an im-
pact on their own health. This does highlight the im-
portance of anticipating the possibility of important
results being generated and to establish protocols to in-
clude family members in the consent process and to en-
sure robust pathways are in place for the delivery of
results in situations such as this.
Case study 2: categories 1 and 2 (medically actionable and
potential clinically utility) - inherited predisposition to can-
cer and potential implications to current therapy
Scenario A 56 year old female underwent surgery for
pancreatic cancer and provided standard APGI consent.
Significance of finding Germline analysis revealed the
presence of a deleterious mutation in exon 11 of the BRCA2
gene (c.5410_5411delGT). This mutation would be ex-
pected to produce the BRCA2 inherited breast cancer
phenotype. Results were verified using a diagnostic grade
assay in a certified laboratory, and a formal report was
issued.
Description of specific ethical and practical issues
The participant was alive and undergoing second line
treatment for metastatic disease. Results were communi-
cated directly to the treating clinician due to immediate
potential clinical utility. At the time the participant was
alive and progressing on the current chemotherapy regi-
men. The treating medical oncologist discussed the find-
ings with the participant, and offered the opportunity to
switch to a therapy thought to be active in other cancers
with this mutation [30,44].
The participant opted for the suggested change in
treatment. Meanwhile, the participant was also referred
to a familial cancer clinic for counseling and further test-
ing. The participant had no siblings or children to be in-
cluded in this process. The participant stated that she
'was happy hearing of this finding… and looking forward
to a shot at a different treatment that might suit me bet-
ter'. At last follow up, the participant was alive with
stable disease on therapy.
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represents an equivalent result and expected phenotype
as the previous case, it has unique and specific ethical
considerations. In contrast to the previous case, the
treating medical oncologist was the initial gatekeeper of
the information as the participant was still alive and
there were potential therapeutic implications. Due to the
progressive nature of the participant’s disease, the clin-
ical utility was deemed by the clinical teams to be the
greater priority in this instance. This demonstrates that
whilst two results can be categorized similarly, the cir-
cumstances and outcomes can be very different,
highlighting the importance of context.Case study 3: category 2 (potential clinical utility through
change of diagnosis)
Scenario A 32 year old female underwent biopsy for
pancreatic cancer and provided standard APGI consent.Significance of finding Somatic analysis detected muta-
tions in BRAF (V600E) with wild-type KRAS and loss of
heterozygosity (LOH) of the APC locus. Polymerase
chain reaction and pyrosequencing in a NATA accre-
dited (CLIA equivalent) diagnostic laboratory confirmed
wild-type KRAS and BRAF (V600E) mutations. This mu-
tation pattern was consistent with a colonic rather than
a pancreatic carcinoma [45]. Results were reported to
the treating medical oncologist and surgeon. On receipt
of new information, further investigations were under-
taken, and a primary colonic adenocarcinoma was
identified.Description of specific ethical and practical issues Re-
sults were communicated directly to the treating clinical
team (surgeon and medical oncologist) due to potential
diagnostic significance, and subsequently discussed with
the participant and family. Due to the clinical implica-
tions, an early decision to expedite confirmatory testing
and reporting of results was made. The prognosis for co-
lonic carcinoma is greatly different to that of pancreatic
adenocarcinoma, and influences decisions with regard to
clinical management.Conclusions and recommendations Return of research
results has implications beyond incidental or secondary
findings related to adult onset diseases and can have im-
mediate value. For those undertaking prospective obser-
vational studies, we would suggest that strategies be
developed within a framework for returning results, spe-
cific to such situations where the stakes are high and the
timeline is important.Discussion
This exploration of the foundations, processes and practi-
calities of returning research results to participants dem-
onstrates that research results can be returned to treating
clinicians and patients in a meaningful way, with positive
outcomes. We demonstrate that opportunities for alterna-
tive treatment options can be introduced through this
mechanism, which can ultimately benefit the individual.
This is especially pertinent to rapidly fatal diseases such
as pancreatic cancer where prognosis remains poor using
standard approaches. This report was not intended to
further stimulate the debate about whether to return
research results or not, but rather to provide empirical
evidence illustrating the realistic challenges and oppor-
tunities that exist.
It is relevant that mechanisms to manage these pro-
cesses, such as an ethically defensible plan, are considered
from the outset, formally documented and implemented
in a multi-disciplinary environment. It is important that
such frameworks are not devised as blanket rules, but are
dynamic so that they can be adapted in response to the
context of the result, the participant, the growth of refer-
ence data and changes in guidelines and policy.
These data also provide insights into participant prefer-
ences, and how these views can differ from that of re-
searchers and ethical review boards as 95% of participants
opted-in for the return of meaningful research results.
Human research ethics committees are obliged under
Australian ethical guidelines to review the appropriateness
of plans to communicate results or not to do so, but inter-
estingly only 3 of 14 committees acknowledged the ethic-
ally defensible plan, or made remarks on the return of
results issue in any way. Further to this, we initially sought
ethics committee guidance on this issue, and were met
with limited direction, recommendation, references or
advice. This suggests that perhaps ethical review boards
lack the knowledge or expertise to guide researchers ad-
equately on this topic. It will be important that policies
and guidelines are established to guide ethics boards when
advising on return of research results.
More data are required concerning operability, cost and
infrastructure requirements for returning research results,
but these should assess not only the cost but also the po-
tential savings and benefits of using genomic information
to guide clinical decision-making. There would be little
point in developing policies to return research results but
not provide the capacity or resources to do so. We highlight
the importance of relationships between researchers and
clinicians and participants, making communicability less
troublesome and ultimately less costly. Furthermore, the
preparation and coordination of disclosure was performed
by a member of the research team who carries out a liaison
role, and is intimately involved in communicating between
the researchers, clinical teams and participants. Researchers
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the research team who is an effective communicator and
has a clinical sciences background.
The case studies also highlight the issue of where in the
care continuum obligations exist for genomic information.
One can predict that results will continue to emerge
throughout the life of a patient post-diagnosis, as those
findings that are of unknown significance at present will
presumably not always be so. Limiting the duration of ob-
ligation of researchers to return results is likely a practical
necessity and should be made clear to potential partici-
pants during the informed consent process.
We acknowledge these data have limitations. The pa-
tient group is clinically homogenous and mostly under
the management of specialist clinical teams. These find-
ings may not generalize to all individuals who are
asymptomatic and have no personal or family history of
cancer. Nevertheless, we argue that this is perhaps the
ideal setting for returning results, as it ensures that the
persons responsible have a well-established relationship
with the patient and also have the necessary opportunity
to communicate with them.
Conclusions
The literature is replete with commentaries regarding the
risk of disclosing research findings. With the lack of real
life case studies, the benefits are rarely if ever discussed.
The benefits, as shown by this report, are tangible and en-
during. It is prudent for funding bodies, policy makers
and governments to work with research and patient com-
munities to build an evidence base and conduct appropri-
ate research and analysis whilst articulating appropriate
guidelines and policies. Investment in the ability to return
research results is not only an ethical imperative but is of
fundamental importance to the translational research
process, as it affirms participants as true partners in the
adoption of genomic medicine.
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